ArticleNational science review2021
COVID-19 reinfection in the presence of neutralizing antibodies.
Article in National science review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- Impact of maternal COVID-19 infection on offspring immunity and maternal-fetal outcomes at different pregnancy stages: a cohort study.BMC pregnancy and childbirth · 2025Observational
- From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019.Clinical & translational immunology · 2024Review
- Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.Frontiers in immunology · 2023Review
- Article
- Multiple SARS-CoV-2 Reinfections: A Case Series of Thrice-Infected Individuals.Mayo Clinic proceedings · 2022Article
- Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2-Seropositive Individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.Cell reports. Medicine · 2022Article
- Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses.Frontiers in immunology · 2022Review
- Article
- Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?The Lancet. Respiratory medicine · 2021Review
- Distinguishing repeated polymerase chain reaction positivity from re-infections in COVID-19.Influenza and other respiratory viruses · 2021Article
- Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.Journal of medical virology · 2021Article
- SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19.New microbes and new infections · 2021Article
- Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.Cellular & molecular immunology · 2021Article
- Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases.Cell & bioscience · 2021Article
- Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters.Frontiers in microbiology · 2021Article
- Fighting SARS-CoV-2 with green seaweedPeerJ · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After a short recovery period, COVID-19 reinfections could occur in convalescent patients, even those with measurable levels of neutralizing antibodies. Effective vaccinations and protective public health measures are recommended for the convalescent COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.